Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window of Opportunity Trial of Olaparib and Durvalumab in Breast Cancer
NCT03594396Phase 2Active, not recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2018
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab in breast cancer, sponsored by Seoul National University Hospital. Started Jun 2018; status: active, not recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03594396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594396.